Most popular programs
Trending now
Gregory Mario and Jeremy Mario Professor of Business Administration at Duke University
Reed SD, Li Y, Kamble S, et al. Introduction of the TEAM-HF costing tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions. Circ Cardiovasc Qual Outcomes;5(1):113-119. Greiner MA, Hammill BG, Fonarow GC, et al. Predicting high costs among Medicare beneficiaries with heart failure. Am J Cardiol;109(5):705-711. Glickman SW, Galhenage S, McNair L, et al. The potential influence of Internet-based social networking on the conduct of clinical research studies. J Empir Res Hum Res Ethics;7(1):71-80. Dinan MA, Robinson TJ, Zagar TM, et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys;82(5):e781-e786. DeWitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Schulman KA, Reed SD. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. Value Health;15(2):277-283. Baras AI, Baras AS, Schulman KA. Drug development risk and the cost of capital. Nat Rev Drug Discov;11(5):347-348. Curtis LH, Hammill BG, Qualls LG, et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 Medicare beneficiaries. Am J Ophthalmol;153(6):1116-1124.e1. Dinan MA, Curtis LH, Carpenter WR, et al. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among Medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol;30(22):2725-2730. Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. Value Health;15(5):632-638. Gellad ZF, Muir AJ, McHutchison JG, et al. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. Value Health;15(6):876-886. Reed SD, Li Y, Ellis SJ, et al. Associations between hemoglobin level, resource use, and medical costs in patients with heart failure: findings from HF-ACTION. J Card Fail;18(10):784-791. Reed SD, Li Y, Dunlap ME, et al. In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol;110(8):1150-1155. Valverde AM, Reed SD, Schulman KA. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases. Health Aff (Millwood);31(11):2528-2535.
Kevin A. Schulman, MD, MBA, is a Professor of Medicine, Associate Chair of Business Development and Strategy in the Department of Medicine, Director of Industry Partnerships and Education for the Clinical Excellence Research Center (CERC) at the Stanford University School of Medicine, and, by courtesy, Professor of Economics at Stanford’s Graduate School of Business. He is the Brainlab case study instructor for BUS5.1x. In 2013, he served as a visiting professor of business administration at Harvard Business School. At Duke, he is an associate director of the Duke Clinical Research Institute in the School of Medicine, the country's largest academic clinical research organization. At Duke's Fuqua School of Business, he served for more than a decade as the director of the Health Sector Management program and the Master of Management in Clinical Informatics degree program. He is President of the Business School Alliance for Health Management (BAHM).